A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: resembling (46)

Finance and Performance Reports 2023-24 Month 2 May 2023

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 2 9
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-2-May-2023.pdf

Atezolizumab-Carboplatin(AUC5)-Etoposide(IV/PO)

Description
Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen  Lung - Atezolizumab-Carboplatin (AUC5)-Etoposide(IV/PO
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-CarboplatinAUC5-EtoposideIVPO.pdf

Atezolizumab-Bevacizumab-Carboplatin(AUC6)-Paclitaxel

Description
Chemotherapy Protocol LUNG CANCER ATEZOLIZUMAB-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen  Lung-Atezolizumab-Bevacizumab-Carboplatin (AUC6)-Paclitaxel Indication  The treatment of adult
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab-Bevacizumab-CarboplatinAUC6-Paclitaxel.pdf

Bevacizumab (15mgkg), Carboplatin and Gemcitabine (1,8)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER BEVACIZUMAB (15)-CARBOPLATIN (AUC4)-GEMCITABINE (day 1, 8) Regimen • Ovary-Bevacizumab (15)-Carboplatin (AUC4)-Gemcitabine (1, 8
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Bevacizumab15mgkgCarboplatinAUC4Gemcitabineday18.pdf

Carboplatin (AUC5) -Pegylated Liposomal Doxorubicin Retreat

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5) – PEGYLATED LIPOSOMAL DOXORUBICIN (Caelyx) Retreat Please note this protocol is based on information for the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/Carboplatin-AUC5-Pegylated-Liposomal-Doxorubicin-Retreat-Caelyx.pdf

Carboplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC 5)-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Carboplatin (AUC5)-Pembrolizumab-Pemetrexed Indication • Pembrolizumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pembrolizumab-Pemetrexed.pdf

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description
Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

UHS Inclusion and Belonging Strategy

Description
Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

Rituximab-Gemcitabine-Oxaliplatin (R-GemOx)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB-GEMCITABINE-OXALIPLATIN (R-GemOx) Regimen • Lymphoma – Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) Indication • Salvage regimen for relapsed/refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-Gemcitabine-Oxaliplatin-R-GemOx.pdf

PV-CHP Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-POLATUZUMAB VEDOTIN-PREDNISOLONE- RITUXIMAB Regimen • Lymphoma – Cyclophosphamide-doxorubicin-polatuzumab vedotin -prednisolone – rituximab Indication • Previously untreated diffuse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/PV-CHP-Cyclophosphamide-doxorubicin-polatuzumab-vedotin-prednisolone.pdf
661 to 670 of 761
Previous … 65 66 67 68 69 … Next